Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 2Unknown 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Melanoma 3Uveal Melanoma 1Neoplasms 1Neoplasm Metastasis 1

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × Monophenol Monooxygenase × Clear all
NCT00084656 2022-04-14

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Bristol-Myers Squibb

Phase 2 Completed
77 enrolled 13 charts
Dermatologic

Uveal Melanoma, Melanoma

NCT00153569 2010-05-26

Multiepitope Peptide Vaccination in Melanoma

Charite University, Berlin, Germany

Phase 2 Unknown
25 enrolled
Dermatologic

Melanoma

NCT00001685 2008-03-04

Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
114 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡